ReNeuron Group plc Block Listing Review and TVR (3153Z)
31 August 2018 - 4:00PM
UK Regulatory
TIDMRENE
RNS Number : 3153Z
ReNeuron Group plc
31 August 2018
31 August 2018 AIM: RENE
ReNeuron Group plc
("ReNeuron" or the "Company")
Block Listing Review and Total Voting Rights
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, provides the following
update in accordance with Schedule Six of the AIM Rules for
Companies regarding its existing block listing arrangements.
Name: ReNeuron Group plc
Name of Scheme: ReNeuron Share Option Schemes
-------------------------------
Period of Return: From 1 March 2018 to 31 August
2018
-------------------------------
Balance of unallotted securities 902,825 Ordinary Shares (of
under scheme(s) from previous 1p each)
return:
-------------------------------
Plus: The amount by which N/A
the block scheme(s) has been
increased since the date
of the last Review (if any
increase has been applied
for):
-------------------------------
Less: Number of securities
issued/allotted under scheme(s) N/A
during period
-------------------------------
Equals: Balance under scheme(s) 902,825 Ordinary Shares
not yet issued/allotted at
end of period:
-------------------------------
Number and class of securities 20,000 ordinary shares on
originally admitted and the 13 May 2010
date of admission:
-------------------------------
Total Voting Rights
The Company has 31,646,186 Ordinary Shares in issue, all with
voting rights. The Company holds no Ordinary Shares in treasury.
The figure of 31,646,186 Ordinary Shares may be used by
shareholders as the denominator for the calculation by which they
will determine if they are required to notify their interest in, or
a change in their interest in, the Company under the FCA's
Disclosure and Transparency Rules.
ENDS
ENQUIRIES:
ReNeuron +44 (0)20 3819 8400
Olav Hellebø , Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan +44 (0) 20 7466 5000
Mark Court, Sophie Wills, Tilly Abraham
Stifel Nicolaus Europe Limited +44 (0) 20 7710 7600
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)
Nplus1 Singer Advisory LLP +44 (0) 20 7496 3000
Mark Taylor (Joint Broker)
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development
company. Based in the UK, its primary objective is the development
of novel cell-based therapies targeting areas of significant unmet
or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop
cell-based therapies for significant disease conditions where the
cells can be readily administered "off-the-shelf" to any eligible
patient without the need for additional immunosuppressive drug
treatments. The Company has therapeutic candidates in clinical
development for disability as a result of stroke and for the
blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential new nanomedicine targeting cancer and as a
potential delivery system for drugs that would otherwise lack
adequate capacity to penetrate to their site of action.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. Further information on ReNeuron and its products can
be found at www.reneuron.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCBSGDIUUXBGIG
(END) Dow Jones Newswires
August 31, 2018 02:00 ET (06:00 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2024 to May 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From May 2023 to May 2024